Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X842 in Healthy Subjects
NCT03105375Phase 1Completed
- Sponsor
- Cinclus Pharma
- Start
- Feb 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of linaprazan glurate in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Cinclus Pharma. Primary endpoint: Adverse Events at 5 weeks. Started Feb 2017; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03105375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105375.